Cerebrotech Receives CE Mark for Non-Invasive Brain Monitor
Pleasanton, CA, August 25, 2015 --(PR.com)-- Cerebrotech Medical Systems, a privately held medical device company focused on non-invasive brain monitoring, today announced it has received a CE Mark for its Intracranial Fluids Monitor. The approval by the European notified body, BSI, represents the culmination of years of research at the University of California at Berkeley, under the direction of Prof. Boris Rubinsky, and four years of product development and clinical testing by the company.
“We are very pleased to receive this validation of our technology. With clearance to commercialize in Europe, the company is moving into the next stage of its mission to significantly improve the clinical pathway and standard of care for patients with brain injuries,” said Mitch Levinson, the company’s co-founder and CEO.
Wade Smith, Ph.D., M.D., Director of Neurovascular Services at University of California at San Francisco Medical Center and Chairman of Cerebrotech’s Scientific Advisory Board (SAB), is enthusiastic about the progress he has seen since he joined the SAB in 2011. “It has been remarkable to watch this powerful technology unfold, and to see it realizing the potential that we were only imagining just a few years ago. Cerebrotech’s monitor can give us valuable insight into the progression of edema and bleeding in our patients, and help us manage their care as they recover from stroke and brain trauma.”
About Cerebrotech Medical Systems
Cerebrotech Medical Systems, Inc. was founded in late 2010 with the mission to provide clinicians with a completely non-invasive monitor for early detection of cerebral events that can be catastrophic for patients after stroke, traumatic brain injury, brain surgery and other conditions. With earlier detection, physicians can intervene sooner, saving lives and improving outcomes—all while reducing healthcare costs, including hospital, rehabilitation and long-term care. The company’s core intellectual property is licensed exclusively from University of California at Berkeley. Cerebrotech is a venture capital-backed medical device company located in Pleasanton, CA. www.cerebrotechmedical.com
“We are very pleased to receive this validation of our technology. With clearance to commercialize in Europe, the company is moving into the next stage of its mission to significantly improve the clinical pathway and standard of care for patients with brain injuries,” said Mitch Levinson, the company’s co-founder and CEO.
Wade Smith, Ph.D., M.D., Director of Neurovascular Services at University of California at San Francisco Medical Center and Chairman of Cerebrotech’s Scientific Advisory Board (SAB), is enthusiastic about the progress he has seen since he joined the SAB in 2011. “It has been remarkable to watch this powerful technology unfold, and to see it realizing the potential that we were only imagining just a few years ago. Cerebrotech’s monitor can give us valuable insight into the progression of edema and bleeding in our patients, and help us manage their care as they recover from stroke and brain trauma.”
About Cerebrotech Medical Systems
Cerebrotech Medical Systems, Inc. was founded in late 2010 with the mission to provide clinicians with a completely non-invasive monitor for early detection of cerebral events that can be catastrophic for patients after stroke, traumatic brain injury, brain surgery and other conditions. With earlier detection, physicians can intervene sooner, saving lives and improving outcomes—all while reducing healthcare costs, including hospital, rehabilitation and long-term care. The company’s core intellectual property is licensed exclusively from University of California at Berkeley. Cerebrotech is a venture capital-backed medical device company located in Pleasanton, CA. www.cerebrotechmedical.com
Contact
Cerebrotech Medical Systems
Mitch Levinson
925-399-5392
cerebrotechmedical.com
Mitch Levinson
925-399-5392
cerebrotechmedical.com
Contact
Categories